ImmusanT Announces Initiation of Phase 2 Clinical Trial of Therapeutic Vaccine for Celiac Disease

From ImmusanT Press Release

20 October 2018

Cambridge, MA


“CAMBRIDGE, Mass. – October 30, 2018 – ImmusanT, Inc., a clinical stage company leveraging
its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based
immunomodulatory vaccine therapies to patients with autoimmune diseases, initiated
enrollment in Australia and New Zealand for its Phase 2 RESET CeD study assessing the safety,
tolerability and efficacy of its lead therapeutic candidate, Nexvax2®, in patients with celiac
disease who carry the immune recognition genes for HLA-DQ2.5. The latter accounts for
approximately 90% of the celiac patient population, and Nexvax2 is designed to protect these
patients from the effects of gluten exposure … read more here and here

Other articles related to the Nexvax2 Phase 2 Trials


Related Posts Plugin for WordPress, Blogger...

On November 1st, 2018, posted in: CeliacCorner Blogs by ,

Leave a comment - awaits moderation

Your email address will not be published. Required fields are marked *